Sirtex Medical, a healthcare company providing interventional treatment solutions, has unveiled its SIR-Spheres FLEXdose SELECT Delivery Program to enable new Y-90 treatment.
SIR-Spheres FLEXdose SELECT introduces a new method for delivering precise Y-90 selective internal radiation therapy to treat liver tumours originating from primary colorectal cancer.
SIR-Spheres are a medical device used in selective internal radiation therapy.
It is specifically indicated for use in conjunction with intra-hepatic artery chemotherapy (IHAC) using FUDR (Floxuridine).
The introduction of the FLEXdose SELECT 3mL vial configuration expands Sirtex Medical’s SIR-Spheres portfolio.
The new option enables more personalised Y-90 selective treatment plans tailored to individual patient needs.
The approach provides flexibility by allowing for customised, patient-specific dosing from a single 3mL delivery vial.
According to the healthcare firm, the 3mL SIR-Spheres vials contain around 27 million microspheres, compared to the 44 million in the existing 5mL vials.
With pre-calibration available up to five days in advance, the Y-90 delivery system is designed to offer more precise treatment targeting.
Sirtex Medical CEO Matt Schmidt said: “We’re pleased to introduce this latest innovation in Y-90 radioembolisation therapy to treat a broader spectrum of tumour burden.
“The SIR-Spheres FLEXdose SELECT Delivery Program reflects our continued focus on listening to the needs of patients and physicians by enabling access to personalised Y-90 resin doses and expedited patient treatments.”
In September 2022, the interventional treatment solutions provider secured approval for SIR-Spheres Y-90 resin microspheres for hepatocellular carcinoma (HCC) treatment in Brazil.
The Brazilian National Agency of Supplementary Health recommends SIR-Spheres for the treatment of intermediate and advanced-stage HCC.
In February same year, Sirtex Medical and Grand Pharmaceutical Group obtained new drug application (NDA) approval for SIR-Spheres Y-90 resin microspheres from China’s National Medical Products Administration (NMPA).
